Articles tagged "Pharmacokinetics"

2021 American Transplant Congress
Evaluation of Empiric Extended-Release Tacrolimus Dosing in Adult Kidney Transplant Recipients
C. Patel, S. Lee, D. M. Salerno, N. W. Lange, J. Hedvat
Pharmacy, NewYork-Presbyterian Hospital, New York, NY
*Purpose: Envarsus XR® (extended-release [XR] tacrolimus) is the standard of care tacrolimus formulation at our center for de novo maintenance immunosuppression in adult kidney transplant…
2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
B. Lane¹, U. Kaszubski¹, A. Freeman¹, B. Wise¹, L. Hutchinson¹, M. Janusek¹, G. Therapondos², H. Bohorquez³, S. Anders¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Hepatology, Ochsner Medical Center, New Orleans, LA, ³Transplant Surgery, Ochsner Medical Center, New Orleans, LA
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…
2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
S. Finder, M. Morrison, K. B. Harrison, S. A. Heeney
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…
2021 American Transplant Congress
Evaluate the Effect of Cresemba (isavuconazonium Sulfate) Capsule and Noxafil (posaconazole) Delayed Release Tablets on Tacrolimus Dose to Concentration (D/C) Ratios in Lung Transplant Recipients
H. Sweiss¹, E. Kincaide¹, D. Levine², R. Hall¹
¹University Health, San Antonio, Department of Pharmacotherapy and Pharmacy Services, The University of Texas at Austin, Pharmacotherapy Division, College of Pharmacy, San Antonio, TX, ²University Health, San Antonio, University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: Evaluate the effect of Cresemba (isavuconazonium sulfate) capsule and Noxafil (posaconazole) delayed release tablet on tacrolimus dose to concentration (D/C) ratio in lung transplant.*Methods:…
2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
A. Demirag¹, P. L. Lobo², J. Oberholzer¹, A. Kumar², B. Rawashdeh¹, S. L. Lennon¹, H. N. Guvener Demirag¹, A. Doyle², J. Geystone³, K. L. Brayman¹
¹Transplantation, University of Virginia Medical Center, Charlottesville, VA, ²Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, ³Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
N. Singh¹, T. Le¹, M. S. Naseer¹, S. Asmil¹, A. Palermini¹, A. Qamar¹, R. Chand¹, S. Tandukar¹, D. Aultman², H. Shokouh-Amiri², G. Zibari²
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, ²Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
L. M. Potter¹, B. Vargas², S. M. Rotolo¹, C. McEwen¹, K. Tsui¹
¹University of Chicago Medicine, Chicago, IL, ²Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…
2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
2020 American Transplant Congress
Belatacept Removal by Plasmapheresis: Kinetics, Dose Adjustments and Clinical Recommendations
S. Tremblay¹, N. Wilson¹, B. Miyagawa², H. Kuzaro¹, A. R. Shields³, R. R. Alloway¹, A. Govil¹, J. Kremer⁴, E. Woodle¹, T. Mizuno², A. A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's, Cincinnati, OH, ³U Cincinnati / Christ Hospital, Cincinnati, OH, ⁴Christ Hospital, Cincinnati, OH
*Purpose: Belatacept (BELA), a protein immunosuppressant, has limited available pharmacokinetic (PK) data. Available PK data, limited to product development analyses, shows moderate intrapatient variability with…
2020 American Transplant Congress
Largest Experience of Safety, and Efficacy of Patiromer in Solid Organ Transplants (SOT)
P. Singh¹, H. Winters², T. E. Pesavento¹, K. Schnelle²
¹Transplant Nephrology, Ohio State University, Columbus, OH, ²Transplant Pharmacy, Ohio State University, Columbus, OH
*Purpose: Hyperkalemia, a potentially life‐threatening electrolyte abnormality, is commonly seen SOT. The predisposing factors are renal-dysfunction, and medications (CNI, TMP-SMX, ACEI, and ARBs). Patiromer, a…